Persistent Gut Microbiome Alterations in Cushing's Syndrome Post-Remission

Overview

This study demonstrates that patients with endogenous Cushing's syndrome (CS) exhibit a distinct gut microbiome dysbiosis during active disease that persists even 1 to 2 years after biochemical remission following surgery. The microbial profile of CS patients differs significantly from both obese controls and healthy lean individuals, suggesting long-lasting microbiome alterations.

Background

Cushing's syndrome is characterized by chronic endogenous hypercortisolism, leading to metabolic and cardiovascular comorbidities and increased morbidity and mortality. Despite surgical cure, patients often retain elevated health risks, possibly due to lasting biological imprints of cortisol excess. The gut microbiome has been implicated in metabolic diseases and may be altered in CS, but longitudinal data on microbiome changes before and after remission are limited.

Data Highlights

Key Findings

• Patients with active CS show significant gut microbial dysbiosis compared to healthy lean controls.
• This dysbiosis persists in CS patients even 1 to 2 years after surgical remission of hypercortisolism.
• The gut microbiome of CS patients differs from that of obese controls, indicating changes are not solely due to obesity.
• Specific bacterial taxa associated with cortisol metabolism, such as Ruminococcus gnavus, are elevated in active CS.
• Microbial richness remains reduced in CS patients post-remission, consistent with previous studies.

Clinical Implications

Persistent gut microbiome alterations in CS patients after remission suggest that hypercortisolism induces long-lasting changes in microbial communities. These findings highlight the potential for targeted probiotic or microbiome-modulating interventions to restore a healthy gut microbiome and possibly improve metabolic and cardiovascular outcomes in CS patients post-treatment.

Conclusion

Endogenous Cushing's syndrome is associated with a distinct gut microbiome dysbiosis that endures beyond biochemical remission, indicating a sustained microbial imprint of hypercortisolism. Addressing this persistent dysbiosis may represent a novel adjunctive therapeutic strategy.

References

1. Valassi et al 2021 -- Gut Microbiome in Cushing's Disease Remission
2. Zhang et al 2022 -- Microbial Composition in Newly Diagnosed Cushing's Syndrome
3. Endocrine Society Guidelines 2015 -- Diagnosis and Treatment of Cushing's Syndrome